Latest News & Updates

New Protocol Updates Available For The National Gold Card Program
September 20, 2024

Continue Reading »

FDA approves atezolizumab and hyaluronidase-tqjs for subcutaneous injection
September 12, 2024

Continue Reading »

Prescription for Change: Doctors Cast Their Votes for a Healthier Future
August 28, 2024

Continue Reading »

Centers for Medicare & Medicaid Services (CMS) Releases the First Ten Drug Prices Negotiated in IRA Process for Part D
August 28, 2024

Continue Reading »

FDA approves inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer
October 11, 2024

Continue Reading »

FDA approves neoadjuvant/adjuvant nivolumab for resectable non-small cell lung cancer
October 7, 2024

Continue Reading »

FDA approves selpercatinib for RET fusion-positive medullary thyroid cancer
September 29, 2024

Continue Reading »

FDA approves osimertinib for locally advanced, unresectable (stage III) non-small cell lung cancer following chemoradiation therapy | FDA
September 25, 2024

Continue Reading »

Get More from FLASCO With Your Partnership

The Corporate Partnership Program allows FLASCO to expand our offerings to our partneres. Every FLASCO meeting also provides the industry representative with opportunities to educate our partners. When you send representatives to a FLASCO meeting, you are allowing them to share their knowledge, as well as receive the same knowledge as our members by participating within the educational sessions. This helps ensure that the hematology and oncology community at large are learning, sharing best practices, and finding solutions to problems together.

Corporate Partners

Diamond Elite

Diamond

Platinum

Gold

We're Here to Help Contact Us

Contact Us

Add your name, email & message below: